Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.